Featured Articles

 BioNTech SE and CureVac N.V. announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA)…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of…
Read More...

Roche announced that the European Commission (EC) has approved a label extension for Evrysdi (risdiplam) to include a new, room-temperature stable tablet for people living with spinal…
Read More...

Bayer announced that the U.S. Food and Drug Administration (FDA) has approved its oral androgen receptor inhibitor, NUBEQA (darolutamide), for the treatment of adult patients with…
Read More...

Regeneron Pharmaceuticals, Inc. announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited (“Hansoh”) to acquire exclusive clinical development and…
Read More...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease,…
Read More...

The AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the primary endpoint of a statistically…
Read More...

BioNTech SE and Bristol Myers Squibb announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational…
Read More...

Biogen Inc. and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, announced a strategic collaboration to…
Read More...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce the U.S. Food and Drug Administration (FDA) has accepted for review…
Read More...

Eli Lilly and Company and SiteOne Therapeutics, Inc. announced a definitive agreement for Lilly to acquire SiteOne. The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor…
Read More...

GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab for two proposed indications: The first indication is as an add-on maintenance treatment of asthma in…
Read More...

UCB, a global biopharmaceutical company, and Domino Data Lab, provider of a leading data science platform trusted by the world’s largest enterprises, announced a strategic collaboration…
Read More...

Bristol Myers Squibb announced that the European Commission (EC) has approved the perioperative regimen of neoadjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and…
Read More...

Pfizer Inc. announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the…
Read More...

Septerna, Inc. and Novo Nordisk announced an exclusive global collaboration and license agreement to discover, develop and commercialise oral small molecule medicines for obesity, type…
Read More...

AbbVie announced that EMRELIS (telisotuzumab vedotin-tllv) has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with…
Read More...

GSK plc and Boston Pharmaceuticals announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Efimosfermin is…
Read More...

Roche, the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation, announced today statistically significant final overall…
Read More...